Proton Therapy in the Treatment of Liver Metastases
Public ClinicalTrials.gov record NCT01697371. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I-II Trial of Stereotactic Body Proton Therapy for Patients With Liver Metastases
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Local control of hepatic metastases appears to be a major determinant of overall survival. However, many patients are not suitable for resection due to medical or surgical reasons. Therefore, there is an important role for a treatment that can provide the equivalent of tumor resection with minimal morbidity. Stereotactic body radiotherapy (SBRT) delivers an ablative regimen of highly focused external beam radiotherapy that targets one or more discrete extracranial lesions. Published reports using SBRT to treat liver metastases have shown actuarial local control rates ranging from 50-100% with higher doses associated with better local control. In patients with metastatic liver disease, aggressive local therapy using modern radiotherapy techniques are promising and project to have a substantial role in the treatment of metastatic liver cancer to treat unresectable disease. The dosimetric advantage of proton therapy may lead to improved clinical outcomes with less morbidity, however, there is no clinical data to confirm this assertion. We thus propose a phase I study to determine the feasibility and safety of stereotactic body proton therapy in patients with liver metastases followed by a phase II study to determine the efficacy of such treatment on local control.
Study identification
- NCT ID
- NCT01697371
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 35 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 21, 2012
- Primary completion
- Aug 31, 2028
- Completion
- Aug 31, 2033
- Last update posted
- Jun 4, 2026
2012 – 2033
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Loma Linda University Medical Center | Loma Linda | California | 92354 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Liver Metastases trials
Other public records listing Liver Metastases. Sorted by last update posted; newest first. Not a recommendation.
- NCT07791446: End Hole vs. Pressure-Modulated Delivery of Y-90 Resin Microspheres to Liver Metastases. Not yet recruiting
- NCT07717437: DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection. Recruiting
- NCT04020276: OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases Recruiting
- NCT06300463: Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases Recruiting
- NCT06258525: SAMe in Prevention of Oxaliplatin-associated Liver Injury Not yet recruiting
- NCT07281924: Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01697371, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 4, 2026 · Synced Jul 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01697371 live on ClinicalTrials.gov.